3-Bromo-2-Nitropyridine

We are 3-Bromo-2-Nitropyridine CAS:54231-33-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:3-Bromo-2-Nitropyridine
CAS.NO:54231-33-3
Synonyms:3-Bromo-2-nitropyridine;
Molecular Formula:C5H3BrN2O2
Molecular Weight:202.99400
 
Physical and Chemical Properties:
Density:1.833;
Melting point:102-104oC;
Boiling point:256.9oC;
Flash point:109.2oC;
Index of Refraction:1.614;
 
Specification:
Appearance:Light yellow powder
Purity:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate for organic synthesis

3-Bromo-2-Nitropyridine


Related News: Many branded versions of drugs are currently more expensive in China than in other major markets. They could now be subjected to a centralized procurement program where manufacturers will have to go through a bidding process to get the right to supply drugs to public hospitals, the National Health Commission said in a document published on late Friday.1,3-difluorobenzene CAS:372-18-9 Under the terms of this agreement, Inceptua will support Onconova through the pre-approval provision of intravenous rigosertib initially into a number of countries including: Australia, Denmark, Finland, France, Ireland, Italy, the Netherlands, Portugal, South Africa, Spain, and the UK.(S)-N-(tert-Butyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide CAS:149182-72-9 Retrogenix’s proprietary cell microarray technology provides a fast, accurate and effective solution for determining the primary target and secondary target (off-target) activities of antibodies, proteins, cell therapies, small molecules and viruses.1,4-Cyclohexanedimethanol ICIG companies currently employ more than 3,000 people and operate 15 manufacturing facilities in Europe and the United States.“CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.

Related Products
Product Name
Ethyl 4-bromobutyrate View Details
2,6-Dimethoxypyridine View Details
Vinyltrimethoxysilane View Details
N2-(S)-1-Ethoxycarbonyl-3-phenylpropyl-N8-trifluoroacetyl-L-lysine manufacturer 2-Bromo-3-methyl-5-chloropyridine manufacturer 4-Fluoro-3-methylaniline manufacturer 6-Chlorooxindole manufacturer 2-(Trifluoromethoxy)benzoic acid manufacturer